Assessing TP53 status in human tumours to evaluate clinical outcome.

T Soussi, C Béroud

Journal: Nature reviews. Cancer 2002;1(3):233-40

PMID: 11902578

Full Text on Nature Publishing Group View on PubMed

Abstract

TP53 is probably the most extensively studied tumour-suppressor gene, and patients with TP53 mutations are known to have a poor outcome. However, inconsistencies in the analysis of TP53 status, and failure to realize that different mutations behave in different ways, prevent us from effectively applying our vast knowledge of this protein in clinical practice. What simple steps can be taken to ensure that patients benefit from our understanding of TP53?

Address: Institut Curie, Université P. & M. Curie, Laboratoire de Génotoxicologie des Tumeurs, Paris, France. [email protected]

DOI: 10.1038/35106009

Link outs

Free resources

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Miscellaneous:

https://assays.cancer.gov/CPTAC-335

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-TP53-2

Subscription / membership required

Full Text Sources:

https://doi.org/10.1038/35106009

MeSH Terms: Amino Acid Substitution, DNA-Binding Proteins, Gene Deletion, Genes, Tumor Suppressor, Genes, p53, Humans, Li-Fraumeni Syndrome, Loss of Heterozygosity, Membrane Proteins, Mutation, Mutation, Missense, Neoplasms, Nuclear Proteins, Phosphoproteins, Point Mutation, Polymorphism, Genetic, Prognosis, RNA Splice Sites, Structure-Activity Relationship, Trans-Activators, Transcription Factors, Transcriptional Activation, Treatment Outcome, Tumor Protein p73, Tumor Suppressor Protein p53, Tumor Suppressor Proteins

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.